Presentation: Cyanocobalamin 1mg film-coated tablets. Indications: Haematological, neurological and other symptoms secondary to vitamin B12 deficiency. Malabsorption of vitamin B12 e.g. due to absence of intrinsic factor (pernicious anaemia), stomach resection, small intestine disease. Para-aminosalicylic acid therapy. Dosage and Administration: Remission Treatment – usually 2 tablets twice daily until full remission, then follow maintenance dose. Maintenance treatment/prophylaxis – usually 1 tablet daily. If suspected neuropathy, use parenteral treatment. Administer Orobalin between meals.
Contraindications: Hypersensitivity to cyanocobalamin or any of the excipients. Warnings and Precautions: None. Interactions: Vitamin B12 absorption from the GI tract can be reduced by aminoglycosides, aminosalicylic acid, anticonvulsants, biguanides, chloramphenicol, cholestyramine, potassium salts, methyldopa and gastric-acid-inhibiting agents (e.g. omeprazole and cimetidine). Clinical relevance of many of these interactions is likely to be small. Pregnancy and Lactation: No known risks during pregnancy. Cyanocobalamin is excreted into human milk. No effects on breastfed infants anticipated at therapeutic doses. Effects on ability to drive/use machines: None/Negligible influence. Undesirable effects: Rare (>1/10,000 to <1/1,000): Anaphylaxis, fever, Urticaria Exanthema, Exanthematous rash, allergic reactions, skin reactions, angioedema. Pack size and Price: Orobalin 1mg x30 film-coated tablets – £9.99. Legal Category: POM. MA Number: PL 48259/0045. MA Holder: Northumbria Pharma Ltd, NetPark Incubator, Thomas Wright Way, Sedgefield, County Durham, TS21 3FD, UK. Date of Revision: November 2020.